OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pulmonary Medicine is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Activity-related dyspnea and exercise intolerance in chronic obstructive pulmonary disease: recent insights	56
Obstructive lung diseases burden and COVID-19 in developing countries: a perspective	35
Drug-induced sarcoidosis-like reactions	29
Drug-resistant tuberculosis: advances in diagnosis and management	26
Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment	24
Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort	22
Advances in bronchoscopic optical coherence tomography and confocal laser endomicroscopy in pulmonary diseases	22
Exhaled breath analysis in interstitial lung disease	21
Respiratory viral infections in the immunocompromised	20
A clinical review of long-COVID with a focus on the respiratory system	20
Hit-hard and early versus step-up treatment in severe sarcoidosis	18
Effectiveness and safety of coronavirus disease 2019 vaccines	18
Home monitoring in asthma: towards digital twins	17
Thoracic computed tomography in the progressive fibrotic phenotype	17
The role of PET in the management of sarcoidosis	16
Sarcoidosis and maligancy: the chicken and the egg?	16
Cyclic alternating patterns and arousals: what is relevant in obstructive sleep apnea? In Memoriam Mario Giovanni Terzano	16
Obesity-related asthma: new insights leading to a different approach	16
The evolving role of radiological imaging in cystic fibrosis	15
Keeping global focus on the many challenges of respiratory tract infections	14
Robotic bronchoscopy for peripheral pulmonary lesions: a convergence of technologies	14
Bacteriophages for bronchiectasis: treatment of the future?	14
Organ involvement and assessment in sarcoidosis	14
Labelling and denominating lung toxicity effects of pesticides	14
Patterns of progression in non-IPF fibrotic interstitial lung disease	13

Coronavirus disease 2019 management	13
Gram-negative pulmonary infections – advances in epidemiology and diagnosis	13
Update on the genetic basis of obstructive sleep apnoea – hype or hope?	12
Care of the postcoronavirus disease 2019 patient	12
COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum	12
Editorial introductions	12
Novel insights in fibrotic pulmonary sarcoidosis	11
Epidemiology and real-life experience in progressive pulmonary fibrosis	11
Editorial: COPD in the COVID-19 era, challenging concepts and developments in COPD, and occupational exposures and susceptibilities	11
Selected updates on chronic obstructive pulmonary disease	11
Senescence in pulmonary arterial hypertension: is there a link?	11
Mass gathering events and transmission of respiratory tract infections: updates pre and post COVID-19 lockdown	11
Bronchoscopic interventions for chronic bronchitis	11
Editorial introductions	10
Bronchoscopic treatment of early-stage peripheral lung cancer	10
Thoracic empyema: aetiology, diagnosis, treatment, and prevention	10
Editorial: Pesticides and lung function	10
Spirometry, computed tomography, comorbidities, oxygen therapy and other topics in chronic obstructive pulmonary disease and an update on silicosis	10
Editorial: Silicosis, asbestos-related diseases, war-site exposures and a variety of topics in chronic obstructive pulmonary disease	10
Editorial: Are we ready for prime time?	10
The persistent problem of persistent air-leaks: approach to management	9
Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators	9
Outcomes of lung transplantation in cystic fibrosis	9
Drug treatment of COVID-19 infection	9
Progress in the radiologic diagnosis of idiopathic pulmonary fibrosis	9
Therapeutic bronchoscopy for malignant central airway obstruction: impact on quality of life and risk-benefit analysis	9
Big data in sarcoidosis	9
COVID-19 and other respiratory tract infections at mass gathering religious and sporting events	8
Evidence from recent clinical trials in fibrotic interstitial lung diseases	8
Severe pulmonary toxicity associated with inhalation of pyrethroid-based domestic insecticides (Bop/Sapolio): a case series and literature review	8
Interstitial lung disease following coronavirus disease 2019	8
The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases	8
Sarcoidosis associated pulmonary hypertension: an update	8
Current hot topics in pulmonary hypertension	8
Cardiac sarcoidosis and neurosarcoidosis – multidisciplinary approach for diagnosis	8
Telerehabilitation in pulmonary diseases	7
Digital outcome measures in pulmonary clinical trials	7
Host-directed therapies for COVID-19	7
Syndromic genetic causes of pulmonary fibrosis	7
Influenza: clinical aspects, diagnosis, and treatment	7
Editorial introductions	7
Management of pneumothorax: an update	7
Whole lung and sequential bronchoscopic lavage for pulmonary alveolar proteinosis	7
Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease	7
An update on bronchopleural fistulae following cancer-related surgery	7
Transbronchial lung cryobiopsy for the diagnosis of interstitial lung diseases	7
Chronic obstructive pulmonary disease and obstructive sleep apnoea overlap: co-existence, co-morbidity, or causality?	6
Nonpharmaceutical interventions for managing SARS-CoV-2	6
Training in interventional pulmonology: a leap into the future	6
Editorial: Endobronchial valve placement for endoscopic lung volume reduction (ELVR): “the start of a new era”	6

The evolving paradigm of precision medicine in lung cancer	6
What is new in mediastinal staging?	6
Infection control in cystic fibrosis: evolving perspectives and challenges	6
Diagnosis of invasive respiratory mycoses in the immunocompromised host	6
Pediatric interventional bronchoscopy: from early limitations to achievable opportunities	6
Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease	6
Asthma diagnosis using patient-reported outcome measures and objective diagnostic tests: now and into the future	6
The lung way home: ready for home monitoring in lung diseases?	6
Altered pharmacology and toxicology during ageing: implications for lung disease	6
Revealing the pathogenic and ageing-related mechanisms of the enigmatic idiopathic pulmonary fibrosis (and chronic obstructive pulmonary disease)	6
How do we expand the lung donor pool?	6
Improving care in lung cancer surgery: a review of quality measures and evolving standards	6
Role of biomarkers in lung nodule evaluation	6
Interventional pulmonology: reflection on the past, perfecting the present and innovating for the future	6
Editorial: COVID pandemic and Lung cancer: challenges lead to opportunities	6
Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype	5
The justification for the progressive fibrotic phenotype	5
Editorial: Coronavirus disease 2019 (COVID-19) - advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges	5
Editorial introductions	5
Transbronchial biopsy vs. bronchoalveolar lavage in interstitial lung disease	5
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease	5
Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era	5
Editorial: Sarcoidosis: now and into the future	5
Pediatric sarcoidosis with diagnostic and therapeutical insights	5
Direct oral anticoagulant use in special populations	5
Editorial: The role of ageing in pulmonary disease	5
Role of extracorporeal membrane oxygenation and surgical embolectomy in acute pulmonary embolism	5